According to FutureWise analysis the market for immune repertoire sequencing to reach US$ 136 million in 2022, and is projected to expand at a CAGR of 7.1%.
The immune repertoire is defined as the sum of T cell receptors and B cell receptors (also known as immunoglobulin) that comprise the adaptive immune system of an organism. B-cell receptor (BCR) and T-cell receptor (TCR) receptors on the surface of B and T cells, respectively, mediate human adaptive immune system protection. Next-generation sequencing (NGS) advancements have enabled the development of immune repertoire sequencing, a powerful new technology for probing the complementary determining region of these receptors. Immune repertoire sequencing has aided in the profiling of antigen-specific information within lymphocytes and has grown in importance in understanding the body's auto-defence mechanisms against foreign agents.
Animals that reproduce and are more suited to their environments are favoured by natural selection. During an immune response, only lymphocytes that have the proper receptor to bind to an antigen in the immune repertoire will be activated and multiply, creating a clone of cells with identical antigen receptors. Understanding the immune repertoire is essential in the development of targeted therapy and immunotherapy, where treatments are being developed that are customised to an individual for improved success. Many medications that affect the immune system are either being researched or are already in use. Assessing the immune repertoire may help with therapy result prediction and side effect monitoring. The use of cytokines as medicines is one example of a treatment that broadens the immune repertoire.
FutureWise Market Research has published a report that provides an insightful analysis of immune repertoire sequencing market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the immune repertoire sequencing market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.
The key factor driving the worldwide immune repertoire sequencing market is the rise in government funding for various pharmacogenomics-based drug recovery techniques. Furthermore, the global market for immune repertoire sequencing is being driven ahead by the quick expansion of numerous therapeutic fields like infectious illnesses, cardiology, oncology, and pain management. Immune repertoire sequencing method development will become more important in the upcoming years if it can produce more specific sample information than existing techniques. Single-cell techniques are anticipated to drive the immune repertoire sequencing market throughout the forecast period due to their capacity to give high-dimensional and detailed information on smaller populations of interest, such as antigen-binding cells. Moreover, issues with immune repertoire sequencing technologies and variations in data collecting and processing among laboratories are some of the main factors that could restrict immunological development. The market's expansion is also anticipated to be hampered by a shortage of skilled staff to carry out immunological repertoire sequencing techniques established in specialised laboratories.